Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy
News Nov 03, 2009
According to a previous study among a large patient population, the median survival time following diagnosis of a glioblastoma recurrence and treatment with conventional therapy (surgery, chemotherapy and radiation) is 6.2 months. The primary objective for the Nano-Cancer® therapy study was to demonstrate an extension of the median survival time in the recruited patient group by three months compared to this historical control group.
In fact, the median survival time of the 59 patients participating in the phase II clinical trials was 13.4 months following treatment with Nano-Cancer® therapy in conjunction with radiation. The median survival time was thus significantly greater, more than double that of the control population.
The results were even more remarkable in that Nano-Cancer® therapy was tested not on newly diagnosed patients with primary tumors but rather as a study involving patients who had already endured treatment with conventional therapies, as well as the unpleasant effects generally associated with these. Following regulatory approval of the new therapy, it is expected that it will also be available for use in treating other types of localized tumors, as these are generally responsive to the same principle of using warmth to destroy or degrade cancer cells.
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”News
The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.READ MORE